Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for MiNK Therapeutics, Inc. (INKT : NSDQ)
 
 • Company Description   
MiNK Therapeutics Inc. is a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases. MiNK Therapeutics Inc. is headquartered in New York.

Number of Employees: 33

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.31 Daily Weekly Monthly
20 Day Moving Average: 45,402 shares
Shares Outstanding: 33.56 (millions)
Market Capitalization: $43.96 (millions)
Beta:
52 Week High: $22.16
52 Week Low: $1.20
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -43.04% -35.86%
12 Week -54.36% -49.82%
Year To Date -70.63% -64.39%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
149 Fifth Avenue Suite 500
-
New York,NY 10010
USA
ph: 212-994-8250
fax: -
investor@minktherapeutics.com http://www.minktherapeutics.com
 
 • General Corporate Information   
Officers
Jennifer S. Buell - President and Chief Executive Officer
Garo H. Armen - Chairman
Christine M. Klaskin - Treasurer
Peter Behner - Director
Brian Corvese - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 603693102
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/09/22
Share - Related Items
Shares Outstanding: 33.56
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $43.96 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.24 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.96 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.54
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -27.78%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - 1.88
12/31/21 - 2.41
09/30/21 - 0.04
Quick Ratio
03/31/22 - -
12/31/21 - 2.41
09/30/21 - 0.04
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 0.52
12/31/21 - 0.71
09/30/21 - -2.35
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - -
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - -
 

Powered by Zacks Investment Research ©